Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what ...

Gilead Sciences (NasdaqGS:GILD) recently announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, ...

Gilead Sciences (NASDAQ:GILD) is set to report its first-quarter earnings on Thursday, April 24th, after the market closes.

Gilead Sciences has shared positive top-line results from a late-stage study evaluating its antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) with Merck & Co’s anti-PD-1 therapy ...

Analysts have given Gilead Sciences a total of 15 ratings, with the consensus rating being Outperform. The average one-year ...

Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy ...

Gilead Sciences and Sophia Forum, a London-based charity, have launched a campaign to improve HIV care and outreach for women ...

Truist Financial analyst Asthika Goonewardene maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares ...

Gilead Sciences said that it saw positive results from the phase 3 study of its Trodelvy therapy in combination with Merck's Keytruda in patients with inoperable locally advanced or metastatic ...

Gilead Sciences (GILD) announced topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy plus Keytruda ...